Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

00:00

The Dangers of HAVA

This is 18,000 patients in the USU. Like most of these rare diseases, unfortunately, it's awful. Every time I look at one of these, I'm always just like, oh my god, I'm so glad I don't have... It's terrible. The way that this disease is treated today is with a jack inhibitor called jackify from insight. So all the drugs that are being tested for mild fibrosis are all trying to do what Jack-ify does better.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app